Elutia Inc ELUT.OQ reported a quarterly adjusted loss of 33 cents per share for the quarter , higher than the same quarter last year, when the company reported EPS of -57 cents. The mean expectation of two analysts for the quarter was for a loss of 44 cents per share. Wall Street expected results to range from -59 cents to -29 cents per share.
Revenue fell 3.3% to $5.92 million from a year ago; analysts expected $6.60 million.
Elutia Inc's reported EPS for the quarter was a loss of 33 cents.
Elutia Inc shares had risen by 0.5% this quarter and gained 77.3% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts was unchanged in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Elutia Inc is 10.00
This summary was machine generated from LSEG data November 15 at 02:03 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Sep. 30 2024 | -0.44 | -0.33 | Beat |
Jun. 30 2024 | -0.33 | -1.13 | Missed |
Mar. 31 2024 | -0.41 | -0.75 | Missed |
Dec. 31 2023 | -0.28 | -0.40 | Missed |
Comments